Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Reklaim Achieves 40% Year-to-Date Revenue Growth, Retires Debenture, and Strengthens Cash Position

(MYID) Q2 Revenue Up 18% Year-over-Year with Cash Balance Increasing Nearly 20% TORONTO, Sept. 4, 2025 /PRNewswire/ - Reklaim Ltd. ("Reklaim" or the "Company") (TSX: MYID) (OTC: MYIDF) today announ...

How does Reklaim’s Q2 performance compare to its peers in the sector, and does it indicate a sustainable competitive advantage? What implications does the retirement of the debenture have for the company’s capital structure and future financing needs? How will the 40% YTD revenue growth and recent cash balance increase affect the company's valuation and stock price?
Symbol: MYID
Earnings
8 days ago
Read more prnewswire

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

(NYSE:DGX) New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagn...

Are there any regulatory or reimbursement risks that could impact the profitability of the new PGx offering and the stock price? What is the expected market adoption rate for PGx testing relative to competitors like Labcorp and 23andMe, and how might this influence Quest's market share? How will the launch of Quest Diagnostics' advanced pharmacogenomics service affect its revenue forecasts and valuation?
Symbol: DGX
Diagnostics
8 days ago
Read more prnewswire

ZEROSUM "STATE OF THE DEALER" REPORT: NEW AND USED VEHICLE MOVEMENT JUMPS BY 14% AND 16% AS AUGUST SALES REACH YEARLY HIGH

(NYSE:GM) Tariff-Related Cost Increases Are Slower to Materialize than Anticipated; Industry Outlook Moves from Cautious to Cautiously Optimistic GRAND RAPIDS, Mich., Sept. 4, 2025 /PRNewswire/ -- ...

How does GM's sales momentum compare to key competitors like Ford and Stellantis, and what could this mean for market share shifts? What is the expected impact of the slower‑than‑anticipated tariff costs on GM's profit margins and pricing strategy? How will the 14% and 16% increase in vehicle movement affect GM's quarterly earnings forecasts?
Symbol: GM
Auto sales
8 days ago
Read more prnewswire

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

(NASDAQ:REPL) SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges ...

What precedent does this case set for other biotech firms and how could it influence market perception of similar clinical trial disclosures? How might the alleged misstatement about RP1's trial results affect the company's pipeline credibility and future financing? What immediate effect will the lawsuit have on REPL's stock volatility and price?
Symbol: REPL
Lawsuits
8 days ago
Read more prnewswire